Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Dose escalation offers no survival benefits but increases grade ≥ 3 toxicity compared with standard radiation in patients ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...